25 May 2013
Keywords: Pozen, Desitin Arz, MT 400, Sumatriptan and naproxen, Migrain, EU license
Article | 09 May 2012
US drugmaker Pozen (Nasdaq: POZN) has entered into a license agreement with Germany’s Desitin Arzneimittel GmbH, for the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 May 2012
24 May 2013
© 2013 thepharmaletter.com